The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2018 | Cellular therapies in lymphoma
Cellular therapies have been the latest hype in the treatment of blood cancers. In 2017, two CAR T-cell therapies were approved by the Food and Drug Administration (FDA) for the treatment of acute lymphoblastic leukemia (ALL) and advanced lymphomas. John Gribben, MD, DSc, FRCPath, FMed Sci from the Barts Cancer Institute, London, UK discusses some of the advances in this field presented at the European Bone Marrow Transplant 2018 Annual meeting, held in Lisbon Portugal.
